DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/xdrtw2/antibody_drug) has announced the addition of the "Antibody Drug Conjugates: Contract Manufacturing Market, 2014 - 2024" report to their offering.
The base year for the report is 2013. The report provides short-mid term and long term market forecasts for the period 2013 - 2018 and 2019 - 2024, respectively. We have discussed, in detail, the key drivers behind the growth of this market. The estimated sales figures of the ADC therapeutics market forms the basis for our analysis of the forecasted revenues for CMOs. Any changes in the ADC market and its growth are likely to alter the outsourcing activity in the market.
Chapter 2 provides the executive summary of the insights captured during our research. The summary offers a high level view on where the ADC contract manufacturing market is headed in the mid-long term.
Chapter 3 provides a general introduction to antibody drug conjugates. Discussed in detail are the components of an ADC. In addition, the advantages of ADC as a therapeutic drug over traditional treatments are highlighted.
Chapter 4 explores the existing ADC therapeutics, both commercial and under development. Furthermore, the ADC market from the point of view of the commonly used linkers and cytotoxins is analysed.
Chapter 5 presents analysis of the in-house and contract manufacturing of ADCs. There is special focus on CMOs with capabilities to carry out the different steps in ADC manufacturing.
Chapter 6 highlights the regional landscape of CMOs manufacturing components of ADC, conducting conjugation or fill/finish. The analysis has been done by looking at the location of CMOs facilities where these activities are handled.
Chapter 7 includes profiles of some of the CMOs in the ADC market. Each company profile includes information such as financial performance, geographical presence, recent investments for ADC manufacturing and future plans.
Chapter 8 presents analysis of the current and potential future market (in terms of value) for contract manufacturing of ADCs. Market data for base year 2013 and forecasts for the period 2014 - 2024 are presented. The chapter includes, in detail, revenue forecast for manufacturing antibody, drug-linker, conjugation, fill/finish and other components involved in ADC production.
Chapter 9 provides analysis of the strengths, weaknesses, opportunities and threats in the ADC contract manufacturing market. This section captures the key elements likely to influence future growth.
Chapter 10 includes five interview transcripts based on discussion with some of the leading CMOs in the ADC manufacturing market. The CMOs interviewed include Catalent, BSP Pharmaceuticals, Lonza and Piramal Healthcare. One additional CMO which was interviewed requested the details to be published as anonymous.
Chapter 11 summarises the overall report. In this chapter, a recap of the key takeaways is offered and independent opinion based on the research and analysis described in previous chapters.
Chapter 12 and Chapter 13 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.
For more information visit http://www.researchandmarkets.com/research/xdrtw2/antibody_drug